Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	14.55%	254 M€	+11.49%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.94%	1 M€	+0.15%	-
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	2.88%	0 M€	0.00%	-
IQ U.S. MID CAP R&D LEADERS ETF - USD	2.10%	4 M€	+20.15%
ASYMSHARES ASYMMETRIC 500 ETF - USD	1.95%	16 M€	-3.37%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	1.68%	0 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.65%	2 M€	+10.27%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.54%	8 M€	+5.66%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	1.50%	0 M€	0.00%	-
RBC QUANT U.S. EQUITY LEADERS ETF - CAD	0.41%	13 M€	-.--%	-
RBC QUANT U.S. EQUITY LEADERS ETF (D) - CAD	0.41%	4 M€	-.--%	-
RBC QUANT U.S. EQUITY LEADERS ETF - USD	0.41%	3 M€	+15.16%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.37%	17 M€	+7.97%	-
MAIN THEMATIC INNOVATION ETF - USD	0.32%	115 M€	+5.08%	-
HARTFORD DISCIPLINED US EQUITY ETF - USD	0.29%	104 M€	+10.71%
SYNTAX STRATIFIED TOTAL MARKET II ETF - USD	0.20%	7 M€	+6.32%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET HEDGED ETF - USD	0.20%	32 M€	+1.90%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET ETF - USD	0.20%	17 M€	+6.47%	-
ARMOR US EQUITY INDEX ETF - USD	0.17%	9 M€	-.--%	-
HARTFORD MULTIFACTOR US EQUITY ETF - USD	0.17%	375 M€	+9.33%
ADVOCATE RISING RATE HEDGE ETF - USD	0.14%	5 M€	-72.95%	-
SECTOR ROTATION ETF - USD	0.10%	1,487 M€	+9.28%	-
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0.08%	9 M€	+11.21%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.08%	7 M€	+0.11%	-
AMUNDI MSCI USA ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.07%	1,448 M€	-.--%	-
AMUNDI MSCI USA ESG LEADERS SELECT UCITS ETF DR (C) - EUR HEDGED	0.07%	219 M€	+17.17%	-

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-06-12 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.19 USD

Average target price

73.35 USD

Spread / Average Target

+28.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.88%	12.84B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+2.50%	41.34B
BIOGEN INC.	-12.43%	33.72B
UCB	+62.74%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.66%	14.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.34%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.92%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.92B
INNOVENT BIOLOGICS, INC.	-10.64%	8.38B

Biopharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:23:44 2024-05-21 pm EDT			5-day change	1st Jan Change
57.27 ^USD	+0.14%		+0.29%	-8.88%

07:58pm	Incyte Acquires 2 Office Buildings in Delaware	MT
May. 15	Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM